StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
HCTI$2.26+0.00%
Fair $2.26+0.0%

HCTI

Healthcare Triangle, Inc.

Healthcare / Health Information ServicesNasdaqCM

$2.26

+0.00 (+0.00%)

Fairly Valued+0.0%Fair Value $2.26Fund rank 23/100 · Data gapFallback financials|
SA 3/F
F-Score: 2/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 18%

FCF escenarios

weak_data · normalized FCF $-9.3M · quality 32.3/100

Data gap 23/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 15/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

3/100

F

Piotroski

2/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

20/100

SEC 0%

Latest source: unknownPeriods: 6Warnings: 0unknown: 6
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · HCTILocal privado en este navegador · Healthcare Triangle, Inc.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$4M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

N/A

•

Gross Margin

8890.6%

↑

Debt/Equity

N/A

•
No hay histórico de precio usable para pintar el gráfico TradingView.

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2020–2025 · 5 años de histórico normalizado

Revenue CAGR

-15.0%

FCF CAGR

—

FCF margin

-119.0%

FCF / Net income

1.74x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $13.9M · net income $-9.5M · FCF $-16.5M

2020-FY → 2025-FY

Gross margin

8890.6%— pts

Operating margin

-70.5%-74.2% pts

Net margin

-68.2%-75.7% pts

FCF margin

-119.0%— pts
MetricTTM
2025
2024
2023
2022
2021
2020
Income Statement
Revenue$13.9M$13.9M$11.7M$33.2M$45.9M$35.3M$31.3M
Net Income$-9.5M$-9.5M$-6.0M$-8.7M$-14.4M$-5.9M$2.4M
EBITDA$-9.1M$-9.1M$-3.9M$-6.1M$-13.4M$-3.9M$2.0M
EPS-152.30-152.30-16909.30-2.08-3.88-0.200.08
Gross Margin8890.6%8890.6%9148.4%3222.6%———
Operating Margin-70.5%-70.5%-40.6%-23.2%-35.6%-15.2%3.8%
Net Margin-68.2%-68.2%-51.0%-26.2%-31.3%-16.9%7.5%
Cash Flow
Free Cash Flow$-16.5M$-16.5M—$-2.2M$-5.4M——
Returns
ROE——116.7%624.4%-237.7%-41.8%54.4%
Growth & Yield
Revenue Growth18.8%18.8%-64.8%-27.6%30.1%12.5%—
EPS Growth99.1%99.1%-812847.1%46.4%-1820.8%-340.5%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · available periodreconcilia total n/d
Return attribution requires positive start and end prices.

Unavailable: positive start/end prices are required.